B
Brian I. Rini
Researcher at Vanderbilt University Medical Center
Publications - 652
Citations - 49231
Brian I. Rini is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Renal cell carcinoma & Sunitinib. The author has an hindex of 89, co-authored 608 publications receiving 38953 citations. Previous affiliations of Brian I. Rini include University of California, San Francisco & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
TIVO-3: Final OS analysis of a phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC).
Sumanta K. Pal,Bernard Escudier,Michael B. Atkins,Thomas E. Hutson,Camillo Porta,Elena Verzoni,Michael N. Needle,David F. McDermott,Brian I. Rini +8 more
TL;DR: The TIVO-3 study is a phase 3 study designed to compare the efficacy and safety of T with those of sorafenib (S) as 3rd and 4th...
Journal ArticleDOI
Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: The CheckMate 016 study (Journal for ImmunoTherapy of Cancer (2018) 6 (109) DOI: 10.1186/s40425-018-0420-0)
Asim Amin,Elizabeth R. Plimack,Marc S. Ernstoff,Lionel D. Lewis,Todd M. Bauer,David F. McDermott,Michael A. Carducci,Christian Kollmannsberger,Brian I. Rini,Daniel Y.C. Heng,Jennifer J. Knox,Martin H. Voss,Jennifer L. Spratlin,Elmer Berghorn,Lingfeng Yang,Hans J. Hammers +15 more
TL;DR: In this article, the authors propose a solution to solve the problem of the problem: REINFORCE/RESUME 7, 2019....,.. ).
Journal ArticleDOI
On-treatment biomarkers in metastatic renal cell carcinoma: towards individualization of prognosis?
TL;DR: Patients with hypertension continued to survive longer than patients without hypertension, independent of use of antihypertensive agents, sunitinib dose reductions, or both, and on-treatment development of neutropenia or hypertension predicted improved outcomes, and development of both neutropania and hypertension predicted even better outcomes.
Journal ArticleDOI
A phase II study of pazopanib (P) in patients (Pts) with localized renal cell carcinoma (RCC) to enable partial nephrectomy (PN).
Adriana Alvarez,Elizabeth R. Plimack,Robert Dreicer,Timothy D. Gilligan,Jorge A. Garcia,Paul Elson,Steven C. Campbell,Venkatesh Krishnamurthi,Jihad H. Kaouk,Amr Fergany,Robert G. Uzzo,Andrew J. Stephenson,Laura S. Wood,David Y.T. Chen,Brian I. Rini +14 more
TL;DR: A VEGF-targeted agents such as a Paz has shown safety and anti-tumor effect in primary RCC tumors, thus allowing for potential conversion to PN in patients who would otherwise require radical nephrectomy (RN).
Journal ArticleDOI
Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
Mohamed Salem,Shetal N. Shah,Paul Elson,Jorge A. Garcia,Laura S. Wood,Avinash Medsinge,Steven C. Campbell,Robert Dreicer,Brian I. Rini +8 more
TL;DR: In unresectable primary RCC tumors, changes in select CT parameters after 2 cycles of neoadjuvant sunitinib might be associated with the potential for surgical resection.